Table 1.
Baseline patient characteristics (N = 40)
| Characteristic | No. | % |
|---|---|---|
| Median age, years (range) | 64 (46-82) | |
| Sex | ||
| Male | 28 | 70 |
| Female | 12 | 30 |
| FLIPI score | ||
| 0-1 (low risk) | 6 | 15 |
| 2 (intermediate risk) | 14 | 35 |
| 3-5 (high risk) | 20 | 50 |
| Stage | ||
| 1-2 | 7 | 17.5 |
| 3-4 | 33 | 82.5 |
| Bone marrow involvement | 18 | 45 |
| B symptoms | 4 | 10 |
| Elevated LDH | 10 | 25 |
| GELF criteria | 25 | 62.5 |
| FL grade | ||
| I or II | 34 | 85 |
| IIIA | 6 | 15 |
| Median No. of prior therapies (range) | 3 (1-11) | |
| Rituximab | 37 | 92.5 |
| Stem cell transplantation | 8 | 20 |
| Disease status | ||
| Refractory to most recent prior therapy* | 14 | 35 |
| Rituximab refractory* | 18 | 45 |
LDH, lactate dehydrogenase.
*
Refractory status was defined as no response, disease progression, or relapse within 6 months of completing therapy.